Trial Profile
68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 06 Jan 2022 Status changed from active, no longer recruiting to completed.
- 21 Jan 2021 Status changed from suspended to active, no longer recruiting.
- 21 Aug 2020 Planned number of patients changed from 57 to 200.